welcomes you to the new, improved website!The international multicenter CE Mark clinical trial of the HeartMate 3 Left Ventricular Assist System included 50 patients. Thirty-day survival was 98%, bleeding and strokes were observed in 30% and 4%, respectively.
You are here:
Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes
Source: Eur J Cardiothorac Surg
Keywords:
Author(s): Daniel Zimpfer, Ivan Netuka, Jan D. Schmitto, Yuriy Pya, Jens Garbade, Michiel Morshuis, Friedhelm Beyersdorf, Silvana Marasco, Vivek Rao, Laura Damme, Poornima Sood, and Thomas Krabatsch
